Additionally, AAbs such as antinuclear, anti-thyroglobulin, anti-thyroid peroxidase, p53, BRCA2, HUD, and TRIM21 have been identified as predictors of PFS and overall survival (OS) in NSCLC undergoing ICIs therapy (20, 21, 22, 23). The gene discussed is TP53; the disease is non-small cell lung carcinoma.